Funding for Global Cancer Research and Training
The Center for Global Health (CGH) funds research to reduce the global burden of cancer and offers research training opportunities for investigators to strengthen their research abilities.
Sort the table below for current funding opportunities for global cancer research and research training.
Learn more about grants and funding from the National Institutes of Health.
Current Funding Opportunities
Title | Announcement Number | Opening Date | Expiration Date | Additional Resources |
---|---|---|---|---|
Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments | NOT-CA-22-038 | 5/20/2022 | 5/8/2025 | PAR-22-109 PAR-22-106 PAR-22-105 |
Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Support Global Cancer Stigma Research | NOT-CA-23-025 | 12/29/2022 | 5/22/2023 | |
Notice of Special Interest: Administrative Supplement for NCI Global Oncology Mentored Research |
NOT-CA-23-038 | 1/23/23 | 0/23/23 | |
Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments R01 | PAR-23-042 | 12/7/22 | 5/10/23 | |
Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments R61/33 |
PAR-23-043 | 12/7/22 | 3/10/23 | |
Call for Letters of Intent for the NCI’s Global Oncology Research Leadership Training Award | NCI’s Global Oncology Research Leadership Training Award | 3/6/23 | 3/30/23 | An information session will be held on March 17th at 9:00 – 10:30 am ET. Link to join zoom meeting HERE |
Request for Information (RFI): Cancer Therapeutic Clinical Trials in Low- and Middle-Income Countries | NOT-CA-23-015 | 1/13/2023 | 3/10/2023 | Further details about NCI CGH, the strategic plan and currently funded programs |
Co-infection and Cancer (R21 Clinical Trial Not Allowed) | PAR-23-056 | 12/14/2022 | 11/16/2025 | |
Co-infection and Cancer (R01 Clinical Trial Not Allowed) | PAR-23-055 | 12/14/2022 | 11/05/2025 | |
Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional) | PAR-23-042 | 2/09/2023 | Pre-Application Webinar for PAR-23-042 | |
Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control, U54 Clinical Trial Optional) | RFA-CA-22-019 | 10/30/2022 | 11/09/2022 | Pre-Application Webinar for RFA-CA-22-019 |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) | PAR-22-085 | 5/05/2022 | 5/08/2025 | Reissue of PAR-19-193 |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) | PAR-22-086 | 5/16/2022 | 5/08/2025 | Reissue of PAR-19-194 |
Notice of Special Interest (NOSI): Administrative Supplements for NCI Global Oncology Mentored Research | NOT-CA-22-036 | 03/04/2022 | 05/17/2022 |
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Stimulate or Strengthen Global Cancer Health Disparities Research | NOT-CA-22-057 | 03/23/2022 | 05/24/2022 |
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
NOSI: Administrative Supplement for Global Integrative Oncology Research | NOT-CA-22-054 | 02/22/2022 | 05/15/2022 |
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions | NOT-DE-21-010 | 08/06/2021 | 09/10/2024 | |
Notice of Special Interest (NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings | NOT-CA-21-062 | 07/23/2021 | 09/07/2024 | This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program. |
International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed | PAR-21-104 | 01/04/2021 | 03/09/2023 | |
International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required) | PAR-21-105 | 01/04/2021 | 03/09/2023 | |
Notice of Special Interest: Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program | NOT-OD-21-021 | 11/13/2020 | ||
Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments | NOT-CA-22-038 | 10/05/2022 | 05/08/2024 | Interested applicants must submit applications for this initiative using one of the following Dissemination and Implementation Research in Health FOAs:
Reissue of NOT-CA-20-025 |
Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) | PAR-19-194 | 05/16/2019 | 05/08/2022 | Microbial-based Cancer Therapy - Technologies to Overcome Cancer |
Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed) | PAR-19-193 | 05/05/2019 | 05/08/2022 | Microbial-based Cancer Therapy - Technologies to Overcome Cancer |
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | PAR-22-105 | 05/15/2022 | 05/08/2025 | |
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | PAR-22-106 | 05/16/2022 | 05/08/2025 | |
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) | PAR-22-109 | 05/16/2022 | 05/08/2025 |
Training Opportunities
Explore cancer research programs and research training offered and funded through CGH.